Cargando…
Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic
PURPOSE: The COVID-19 pandemic changed diagnostic and treatment pathways in oncology. We compared the safety and efficacy of pembrolizumab amongst advanced nonsmall cell lung cancer (NSCLC) patients with a PD-L1 tumor proportion score (TPS) ≥ 50% before and during the pandemic. METHODS: Advanced NSC...
Autores principales: | Ksienski, Doran, Gupta, Sapna, Truong, Pauline T., Bone, Jeffrey, Chan, Angela, Alex, Deepu, Hart, Jason, Pollock, Philip, Patterson, Tiffany, Clarkson, Melissa, Dissanayake, Dushanthi, Sonke, Eric, Lesperance, Mary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281358/ https://www.ncbi.nlm.nih.gov/pubmed/35834010 http://dx.doi.org/10.1007/s00432-022-04181-0 |
Ejemplares similares
-
Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice
por: Ksienski, Doran, et al.
Publicado: (2021) -
First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic
por: Lakkunarajah, Suganija, et al.
Publicado: (2023) -
Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab
por: Ksienski, Doran, et al.
Publicado: (2021) -
Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors
por: Ksienski, Doran
Publicado: (2011) -
Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab
por: Rittberg, Rebekah, et al.
Publicado: (2022)